Encore to double in size with Empi acquisition
This article was originally published in Clinica
In a bid to bulk up and put more pressure on the competition, US orthopaedics player Encore Medical has announced its intention to acquire Empi, a privately-held developer of products for pain management, orthopaedic rehabilitation and physical therapy. The transaction is valued at around $360m, of which $325m will be paid in cash and the remainder in 8 million Encore shares.
You may also be interested in...
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.